Skip to main
PGEN

Precigen (PGEN) Stock Forecast & Price Target

Precigen (PGEN) Analyst Ratings

Based on 2 analyst ratings
Buy
Strong Buy 50%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Precigen is well-positioned for future growth with a strong clinical pipeline, innovative technology platforms, and a focused strategy on developing precision medicines for a range of diseases. The company's recent approval for Papzimeos in adult recurrent respiratory papillomatosis (RRP) and ongoing efforts to expand its label to include pediatrics and redosing for partial responders, combined with strong launch momentum, indicate potential for significant revenue growth in the coming quarters. Additionally, the company has secured market exclusivity for Papzimeos in the RRP market, providing a competitive advantage and potential for long-term revenue stability. While there are risks associated with clinical, regulatory, and commercial factors, the overall outlook for Precigen is positive, with strong potential for continued success and shareholder value creation.

Bears say

Precigen is presenting positive data at ASCO, which could potentially support the adoption of its precision medicine technology. The company's flagship product, Papzimeos, has shown long-lasting results for patients with immunotherapies and a favorable safety profile. Additionally, management notes that there has been no pushback from payors and all patients have been able to complete the full course of treatment. The high potential for a complete response after a single course and increasing payor willingness should support broader adoption of Precigen's technology, leading to potential future revenues and a higher stock valuation. However, there are still risks involved, including the clinical, regulatory, commercial, partnership, financial, and intellectual property risks that could impact the company's growth and success.

Precigen (PGEN) has been analyzed by 2 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Precigen and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Precigen (PGEN) Forecast

Analysts have given Precigen (PGEN) a Buy based on their latest research and market trends.

According to 2 analysts, Precigen (PGEN) has a Buy consensus rating as of Aug 29, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $14.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $14.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Precigen (PGEN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.